RxDoctor Payments DataLook up a doctor →

Megan Landis, MD

Dermatology · Corydon, INNPI 1558525485

Payments from drug & device makers

$2,757,393in general payments, 2019–2025

Across 967 payments — averaging $2851.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$610K
  • Novartis$500K
  • Amgen$492K
  • Eli Lilly$416K
  • Incyte Corporation$252K
  • Aclaris Therapeutics, Inc.$151K
  • plus $337K from 29 others
$26,805in research payments, 2019–2025

Across 9 payments — averaging $2978.35 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$17K
  • Pfizer$10K

What the payments were for

  • Consulting fees$7,2807%
  • Speaking & faculty fees$65,76463%
  • Travel & lodging$18,05417%
  • Food & beverage$11,69711%
  • Education$8101%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,757,393 in reported general payments places this provider in the 95th percentile of 202 dermatology providers in Indiana.

See all dermatology providers in Indiana

Medicare billing

Part B allowed, 2024
$87,897
Medicare patients
525
Services billed
1,957

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Cosentyx (2 Syringes)Secukinumab12$91,575
OtezlaApremilast12$60,311
Ketoconazole77$1,329
Clobetasol Propionate24$1,245
Fluocinolone Acetonide11$727
Triamcinolone Acetonide53$482
Doxycycline Monohydrate15$472
Doxycycline Hyclate17$411
Spironolactone18$331
Hydrocortisone50$253
ValacyclovirValacyclovir Hcl15$237
Mupirocin15$66

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisCosentyx (2 Syringes)$500,109$91,57512 claims
AmgenOtezla$491,982$60,31112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 202 dermatology providers in Indiana.

Other dermatology in Corydon

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →